Integ. Proteins

Which are the latest news on Integ. Proteins?

Why is Integrated Proteins Ltd falling/rising?

As of 07-Aug, Integrated Proteins Ltd's stock price is 144.00, down 0.62% today and 2.70% over the past month, despite a strong year-to-date increase of 318.60%. Recent trends indicate declining momentum and reduced investor participation, with delivery volume down 46.45% from the 5-day average.

As of 07-Aug, Integrated Proteins Ltd's stock price is currently at 144.00, reflecting a decrease of 0.9, or 0.62%. The stock has underperformed compared to the sector today by 1.34%. Over the past week, the stock has shown a slight increase of 0.45%, but it has declined by 2.70% over the past month, while the benchmark Sensex has gained 0.41% in the same period. <BR><BR>Year-to-date, the stock has performed exceptionally well, with a remarkable increase of 318.60%, contrasting sharply with the Sensex's decline of 7.89%. However, despite this strong year-to-date performance, the stock's recent trend indicates a decline, particularly highlighted by a significant drop in investor participation, with delivery volume falling by 46.45% against the 5-day average. <BR><BR>Additionally, while the stock is currently above its 5-day, 100-day, and 200-day moving averages, it is below its 20-day and 50-day moving averages, suggesting a potential weakening in momentum. These factors collectively contribute to the recent decline in the stock price of Integrated Proteins Ltd.

Should I buy, sell or hold Integrated Proteins Ltd?

What does Integ. Proteins do?

Integrated Proteins Ltd processes oil seeds in the Edible Oil industry and is categorized as a Micro Cap company, with a market cap of INR 267 Cr and reported net sales of 6 Cr and no profit for March 2026. The company has a high P/E ratio of 545.00 and a return on equity of 2.39%.

Overview:<BR>Integrated Proteins Ltd is engaged in the processing of various oil seeds and operates within the Edible Oil industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Integrated Proteins Limited was incorporated as a public limited company in October 1992. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 6 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 267 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 545.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 2.39% <BR>Price to Book: 13.02 <BR><BR>Contact Details:<BR>Address: City Point Opp Town Hall, Station Road Jamnagar Gujarat : 361008 <BR>Tel: 91-288-2551901/902/903 <BR>Email: ps@arcadia.co.in <BR>Website: http://www.integratedproteins.com

How big is Integ. Proteins?

As of 10th June, Integrated Proteins Ltd has a market capitalization of 267.00 Cr, with recent net sales of 9.89 Cr and a net profit of 0.26 Cr. Shareholder's funds are 20.12 Cr, and total assets amount to 32.37 Cr.

As of 10th June, Integrated Proteins Ltd has a market capitalization of 267.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 9.89 Cr and a Net Profit of 0.26 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 20.12 Cr and Total Assets of 32.37 Cr.

Who are in the management team of Integ. Proteins?

The management team of Integ. Proteins includes Vinod P Mehta (Chairman), Arvindbhai Kantilal Shah (Managing Director), Piyush Chimanalal Vora (CFO), Bhalchandra Vyas, and Vijaykumar Shamjibhai Dattani (Independent Directors), and Neepa Praful Kothari (Non-Executive Director). They are responsible for the company's strategic direction and management.

The management team of Integ. Proteins includes the following individuals:<BR><BR>1. **Vinod P Mehta** - Chairman (Non-Executive) & Director (Non-Independent)<BR>2. **Arvindbhai Kantilal Shah** - Executive Director & Managing Director<BR>3. **Piyush Chimanalal Vora** - Executive Director & Chief Financial Officer<BR>4. **Bhalchandra Vyas** - Independent Non-Executive Director<BR>5. **Vijaykumar Shamjibhai Dattani** - Independent Non-Executive Director<BR>6. **Neepa Praful Kothari** - Non-Executive & Non-Independent Director<BR><BR>This team oversees the strategic direction and management of the company.

Who are the peers of the Integ. Proteins?

Integ. Proteins' peers include Sundrop Brands, Shri Venkatesh, Kriti Nutrients, and others, with varying management risk and growth ratings. Integ. Proteins leads in 1-year returns at 222.35%, while Ajanta Soya has the lowest at -47.09%.

Peers: The peers of Integ. Proteins are Sundrop Brands, Shri Venkatesh, Kriti Nutrients, Gokul Refoils, Evexia Lifecare, Vijay Solvex, Ajanta Soya, M K Proteins, and Ramdevbaba Sol.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kriti Nutrients, while Average management risk is found at Sundrop Brands, Shri Venkatesh, Gokul Refoils, Evexia Lifecare, and Ajanta Soya, and the rest. Below Average management risk is noted for Integ. Proteins, Vijay Solvex, and Ramdevbaba Sol. Growth is rated as Excellent for Kriti Nutrients, Average for Integ. Proteins, and Below Average for Sundrop Brands, Shri Venkatesh, Gokul Refoils, Evexia Lifecare, Vijay Solvex, Ajanta Soya, M K Proteins, and Ramdevbaba Sol. Capital Structure is rated as Excellent for Sundrop Brands, Kriti Nutrients, Vijay Solvex, Ajanta Soya, and M K Proteins, Good for Integ. Proteins, and Below Average for Shri Venkatesh, Gokul Refoils, Evexia Lifecare, and Ramdevbaba Sol.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Integ. Proteins at 222.35%, while the lowest is Ajanta Soya at -47.09%. Integ. Proteins' return significantly exceeds all peers. Additionally, the six-month return is negative for Vijay Solvex, M K Proteins, and Ramdevbaba Sol.

Are Integrated Proteins Ltd latest results good or bad?

Integrated Proteins Ltd's latest results are concerning, showing a net profit increase to ₹0.23 crores despite a drastic 73.52% revenue decline to ₹5.69 crores. The company's inconsistent revenue generation and low profitability metrics suggest significant operational challenges, warranting caution for investors.

The latest results for Integrated Proteins Ltd present a mixed picture, but overall, they lean towards the negative side. While the company reported a net profit of ₹0.23 crores in Q4 FY26, which is an increase from ₹0.21 crores in the same quarter last year, this profit comes amid a significant decline in revenue. The company's revenue plummeted by 73.52% year-over-year to just ₹5.69 crores, down from ₹21.49 crores in Q4 FY25. This drastic drop raises serious concerns about the company's operational consistency and ability to generate sustainable revenue.<BR><BR>Moreover, the company has shown a troubling pattern of sporadic revenue generation, recording zero revenue in two of the last four quarters. This inconsistency raises fundamental questions about its business continuity and operational execution. Although the profit margin improved to 4.04% from 0.98% year-over-year, the context of collapsing sales makes this improvement less meaningful.<BR><BR>Additionally, the company's return on equity (ROE) remains very low at 2.41%, and it has a negative return on capital employed (ROCE) of 5.14%, indicating poor capital efficiency. The stock has performed exceptionally well in terms of price appreciation, surging 203.74% over the past year, but this seems disconnected from its underlying financial performance.<BR><BR>In summary, while there are some positive indicators, such as the increase in net profit and profit margin, the overall financial health of Integrated Proteins Ltd appears weak due to erratic revenue generation and low profitability metrics. Investors should approach this company with caution given the significant operational challenges it faces.

When is the next results date for Integrated Proteins Ltd?

The next results date for Integrated Proteins Ltd is 26 May 2026.

The next results date for Integrated Proteins Ltd is scheduled for 26 May 2026.

Is Integ. Proteins overvalued or undervalued?

As of November 27, 2025, Integ. Proteins is considered undervalued with an attractive investment appeal, reflected in its favorable PE ratio of 42.60 and EV to EBITDA of 14.06, despite a year-to-date return of -49.13%, while showing a strong three-year return of 97.78%.

As of 27 November 2025, the valuation grade for Integ. Proteins has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company is currently considered undervalued. Key ratios include a PE ratio of 42.60, an EV to EBITDA of 14.06, and a PEG ratio of 0.11, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Integ. Proteins has a higher PE ratio than CIAN Agro, which stands at 33.9, but lower than Manorama Industries at 43.54. The EV to EBITDA ratio of Integ. Proteins is also more favorable than that of Manorama Industries, which is 28.15. Despite the recent underperformance in the stock's year-to-date return of -49.13% compared to the Sensex's 9.70%, the long-term performance over three years shows a remarkable return of 97.78%, reinforcing the potential for recovery and growth in value.

How has been the historical performance of Integ. Proteins?

Integ. Proteins has shown significant growth, with net sales reaching 21.50 Cr in March 2025, up from 0.24 Cr in March 2024. The company also reported increased operating profit, profit before tax, and profit after tax, alongside a rise in earnings per share to 0.71.

Answer:<BR>The historical performance of Integ. Proteins shows significant growth in net sales, reaching 21.50 Cr in March 2025, up from just 0.24 Cr in March 2024 and 0.17 Cr in March 2023. The total operating income also increased to 21.50 Cr in March 2025, compared to 0.24 Cr in the previous year. The company has seen a notable rise in operating profit, which stood at 0.34 Cr in March 2025, a substantial improvement from 0.14 Cr in March 2024. Profit before tax also increased to 0.32 Cr in March 2025, up from 0.10 Cr in March 2024, while profit after tax reached 0.25 Cr, compared to 0.09 Cr in the prior year. The earnings per share (EPS) rose to 0.71 in March 2025 from 0.26 in March 2024, reflecting a positive trend in profitability.<BR><BR>Breakdown:<BR>Integ. Proteins has demonstrated a remarkable upward trajectory in its financial performance over the past few years. Starting from no sales in previous years, the company achieved net sales of 21.50 Cr in March 2025, marking a significant increase from 0.24 Cr in March 2024. This growth is mirrored in the total operating income, which also reached 21.50 Cr in March 2025. The operating profit has turned positive, with a reported 0.34 Cr in March 2025, compared to a loss of 0.11 Cr in March 2024. Profit before tax and profit after tax have both shown substantial increases, reaching 0.32 Cr and 0.25 Cr respectively in March 2025, indicating improved profitability. The earnings per share have also risen to 0.71, reflecting the company's enhanced financial health. Overall, Integ. Proteins has transitioned from a period of minimal activity to a phase of significant growth and profitability.

Who are the top shareholders of the Integ. Proteins?

The top shareholders of Integ. Proteins include Siddheshwar Advisory Private Limited with 23.89%, and promoter Vinod Prabhulal Mehta with 10.06%. Individual investors collectively hold 47.19%, with no institutional holdings or pledged shares reported.

The top shareholders of Integ. Proteins include Siddheshwar Advisory Private Limited, which holds the largest public share at 23.89%. The promoter with the highest individual holding is Vinod Prabhulal Mehta, who owns 10.06%. Additionally, individual investors collectively hold 47.19% of the company. There are no institutional holdings or pledged promoter shares reported.

What is the technical trend for Integ. Proteins?

As of June 4, 2025, Integ. Proteins shows a mildly bearish trend, with bearish weekly MACD and moving averages, despite mixed signals from the monthly indicators.

As of 4 June 2025, the technical trend for Integ. Proteins has changed from does not qualify to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating a weakening momentum. The daily moving averages are also bearish, reinforcing the negative sentiment. The Bollinger Bands show a mildly bearish stance on the weekly chart, contrasting with a bullish outlook on the monthly chart. The KST is bearish on the weekly timeframe but bullish monthly, suggesting mixed signals. Overall, the current technical stance is mildly bearish, driven primarily by the bearish indicators on the MACD and moving averages.

Has Integ. Proteins declared dividend?

No Dividend History Available